Name: 글로벌 시장 동향
SKU: MRFRPharma6964CR
Availability: InStock

보고서 요약(국문)

세계 페길화 의약품 시장은 2025년부터 2035년까지 연평균 5.17% 성장하여 2035년에는 264억 9,752만 달러에 이를 것으로 예상됩니다. 페길화 제제는 활성 의약품에 페길화 에틸렌(PEG)을 결합시켜 생체 이용률 향상, 체내 순환 시간 연장, 효소 분해 억제 효과를 제공합니다. 이러한 기술은 암, 자가면역 질환, 기타 만성 질환 등 광범위한 질환 치료에 적용 가능하며, 보다 안전하고 효과적이며 투여 횟수를 줄일 수 있도록 합니다.

바이오 의약품 혁신이 시장 성장을 견인
바이오 의약품, 특히 페길화 기술의 발전은 세계 페길화 의약품 시장의 성장을 주도하는 주요 요인입니다. 약물 안정성 향상, 체내 순환 시간 연장, 면역원성 감소 등의 이점 덕분에 페길화 치료제는 복잡한 질환 치료에 매우 효과적인 것으로 나타났습니다. 바이오제약 산업 전체, 즉 생태계는 이러한 발전과 표적 치료에 대한 수요 증가로 인해 이러한 제품들을 빠르게 도입하고 있습니다.

시장 세분화 분석
분자

• 단백질 및 펩타이드: 치료 효과 향상을 위한 생체 공학 분자

o 효소: 대사 기능을 돕는 촉매 치료제
o 압타머: 표적 상호작용을 가능하게 하는 합성 결합체

• 저분자 약물: 빠른 작용을 제공하는 소형 분자

• 지질 나노입자: 효율적인 약물 전달을 위한 최신 벡터

• 리포솜: 제어된 용량 전달을 가능하게 하는 안정적인 운반체

응용 분야

• 종양학: 다양한 암 유형에 대한 맞춤형 치료

• 신경학: 신경 기능 장애를 효과적으로 치료

• 자가면역 질환: 과활성화된 면역 반응을 조절하는 치료제

• 혈액학: 혈액 질환 관리를 지원하는 솔루션

• 기타: 기타 전문 치료 분야

유통 채널

• 병원 약국: 중요하고 필수적인 의약품을 조제합니다.

• 온라인 약국: 간편한 의약품 접근을 위한 디지털 플랫폼입니다.

• 일반 약국: 일상 의약품을 위한 일반적인 유통 채널입니다.

지역별 분석
북미는 PEG화 의약품 시장을 선도하는 지역입니다. 이는 북미 지역의 강력한 연구 개발 역량, 선진적인 의료 시스템, 그리고 꾸준한 규제 승인 덕분입니다. 반면 유럽은 만성 질환 증가, 고령화 인구 증가, 그리고 잘 알려진 제약 혁신 덕분에 성장세를 보이고 있습니다. 아시아 태평양 지역은 성장률 측면에서 가장 빠르게 성장하고 있으며, 이는 암 발병률 증가, 연구 개발 투자 확대, 그리고 의료 접근성 향상에 기인합니다. 기타 지역(RoW) 또한 의료 현대화에 힘입어 꾸준히 성장하고 있으며, 특히 남미, 중동, 그리고 아프리카 일부 지역에서 이러한 추세가 두드러집니다.

전략적 미래 기회
PEG화 의약품은 신흥 시장, 최첨단 약물 전달 기술, 맞춤형 의약품 개발로 인한 상당한 성장 기회 덕분에 밝은 미래를 맞이하고 있습니다. 의료 시스템이 개선되고 표적 치료에 대한 수요가 증가함에 따라 PEG화 제품은 크게 발전할 것입니다. 이러한 추세는 향후 시장 확장을 위한 전략적 이점을 제공하는 데 매우 중요합니다.

주요 보고서 특징

• 시장 규모 2024: 151억 8,126만 달러

• 시장 규모 2035: 264억 9,752만 달러

• 연평균 성장률(CAGR, 2025-2035): 5.17%

• 기준 연도: 2024년

• 시장 예측 기간: 2025-2035년

시장 세분화별 성장

• 분자별: 고분자 의약품 - 5.94%, 저분자 의약품 - 2.87%

• 적용 분야별: 종양학 - 7.73%, 신경학 - 4.72%

• 유통 채널별: 병원 약국 - 4.05%, 온라인 약국 - 7.16%

보고서 요약(영어 원문)

The Global Pegylated Drugs Market is projected to reach USD 26,497.52 million by 2035, growing at a CAGR of 5.17% from 2025 to 2035. PEGylated formulations achieve improved bioavailability, longer circulation time, and better protection from enzymatic degradation by the attachment of PEG to the active pharmaceuticals. This technology enables safer, more effective, and less frequent dosing that is applicable to a wide range of treatments such as cancer, autoimmune disorders, and various other chronic diseases.

Biologics Innovation Driving Market Expansion
Improvements in biologics, especially PEGylation technology, are the main factors that are changing the face of the global PEGylated drugs market. The rise in drug stability, drug circulation over a longer period, and reduced immunogenicity have made PEGylated therapies very successful in the treatment of complicated diseases. The entire biopharma industry, which is the ecosystem, is rapidly adopting these products because of this progress, along with the increasing demand for targeted treatments.

Market Segmentation Breakdown
Molecule
• Protein & Peptide: Bioengineered molecules for enhanced treatment.
o Enzyme: Catalytic therapies aiding metabolic functions.
o Aptamer: Synthetic binders enabling targeted interactions.
• Small Molecular Drugs: Compact molecules offering rapid action.
• Lipid Nanoparticles: Modern vectors for efficient drug transport.
• Liposomes: Stable carriers enabling controlled dosage delivery.
Application
• Oncology: Focused therapies for various cancer types.
• Neurology: Treatments addressing neurological dysfunctions effectively.
• Autoimmune Diseases: Therapeutics moderating overactive immune responses.
• Haematology: Solutions supporting blood disorder management.
• Others: Covers additional specialized therapeutic categories.
Distribution Channel
• Hospital Pharmacy: Dispenses advanced and critical medicines.
• Online Pharmacy: Digital platform for streamlined drug access.
• Retail Pharmacy: Common channel for everyday medications.

Regional Insights
North America is the region that is at the forefront of the PEGylated drugs market. This is mainly due to the region's powerful R&D, sophisticated healthcare systems, and steady regulatory approvals. On the contrary, Europe is obtaining benefits from the increasing prevalence of chronic diseases, aged populations, and well-known pharmaceutical innovations. Moreover, the Asia-Pacific region is the fastest-growing in terms of growth, and this can be attributed to the rising cases of cancer, the investment in R&D, as well as the increasing access to healthcare. The Rest of the World (RoW) is also advancing slowly but steadily with the assistance of healthcare modernization, which is more influential in areas such as South America, the Middle East, and some parts of Africa.

Strategic Future Opportunities
The PEGylated drugs have a bright future with the significant growth opportunities resulting from the emerging markets, the most modern drug delivery technologies, and the personalized medicine development. As the health care system changes for the better and the demand for targeted therapies increases, products that are PEGylated will make significant progress. These trends are of great significance in providing a strategic advantage for the expansion of the market in the future.

Key Report Attributes
• Market Size 2024: USD 15,181.26 Million
• Market Size 2035: USD 26,497.52 Million
• CAGR (2025-2035): 5.17%
• Base Year: 2024
• Market Forecast Period: 2025-2035

Market Segmentation Growth
• By Molecule: Macromolecular Drugs - 5.94%, Small Molecular Drugs - 2.87%.
• By Application: Oncology - 7.73%, Neurology - 4.72%.
• By Distribution Channel: Hospital Pharmacy - 4.05%, Online Pharmacy - 7.16%.

상세 목차

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ..... 18
2 MARKET INTRODUCTION ...... 20
2.1 DEFINITION ....... 20
2.2 SCOPE OF THE STUDY ....... 20
2.3 RESEARCH OBJECTIVE ...... 20
2.4 MARKET STRUCTURE ..... 21
3 RESEARCH METHODOLOGY ...... 22
3.1 OVERVIEW ...... 22
3.2 DATA FLOW ....... 24
3.2.1 DATA MINING PROCESS ....... 24
3.3 PURCHASED DATABASE: ..... 25
3.4 SECONDARY SOURCES: ..... 26
3.4.1 SECONDARY RESEARCH DATA FLOW: ..... 27
3.5 PRIMARY RESEARCH: ..... 28
3.5.1 PRIMARY RESEARCH DATA FLOW: ...... 29
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ..... 30
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE ...... 30
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ...... 31
3.6.1 REVENUE ANALYSIS APPROACH ...... 31
3.7 DATA FORECASTING ...... 32
3.7.1 DATA FORECASTING TYPE ...... 32
3.8 DATA MODELING ...... 33
3.8.1 MICROECONOMIC FACTOR ANALYSIS: ...... 33
3.8.2 DATA MODELING:..... 34
3.9 TEAMS AND ANALYST CONTRIBUTION ...... 37
4 MARKET DYNAMICS ..... 39
4.1 INTRODUCTION ...... 39
4.2 DRIVERS ....... 40
4.2.1 INCREASING INCIDENCES OF CHRONIC DISEASES ....... 40
4.2.2 ADVANCEMENTS IN BIOLOGICS ....... 40
4.2.3 RECENTLY APPROVED PEGYLATED DRUGS ...... 40
4.3 RESTRAINTS ....... 42
4.3.1 HIGH PRODUCTION COSTS ...... 42
4.3.2 REGULATORY HURDLES ..... 43
4.3.3 POTENTIAL SIDE EFFECTS....... 43
4.4 OPPORTUNITY ..... 44
4.4.1 EMERGING MARKETS ..... 44
4.4.2 INNOVATIVE DRUG DELIVERY SYSTEMS ....... 45
4.4.3 PERSONALIZED MEDICINE ....... 45
5 MARKET FACTOR ANALYSIS ...... 46
5.1 PORTER'S FIVE FORCES MODEL ..... 46
5.1.1 THREAT OF NEW ENTRANTS ...... 46
5.1.2 BARGAINING POWER OF SUPPLIERS ....... 47
5.1.3 THREAT OF SUBSTITUTES ....... 47
5.1.4 BARGAINING POWER OF BUYERS ...... 47
5.1.5 INTENSITY OF RIVALRY ..... 47
5.2 IMPACT OF COVID-19 ON THE GLOBAL PEGYLATED DRUGS MARKET ....... 48
5.3 QUALITATIVE ANALYSIS ON ANTI-PEG ANTIBODIES AND IMPACT ON PEGYLATED DRUGS … 50
6 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE ....... 52
6.1 OVERVIEW ...... 52
6.2 MACROMOLECULAR DRUGS ....... 54
6.2.1 PROTEIN AND PEPTIDE ..... 55
6.2.2 ENZYME ...... 56
6.2.3 APTAMER ....... 56
6.3 SMALL MOLECULAR DRUGS ..... 57
6.4 LIPID NANOPARTICLES (LNP) AND LIPOSOMES ...... 57
7 GLOBAL PEGYLATED DRUGS MARKET, BY APPLICATION ...... 58
7.1 OVERVIEW ...... 58
7.2 ONCOLOGY ..... 61
7.3 NEUROLOGY ...... 61
7.4 AUTOIMMUNE DISEASES ..... 62
7.5 HAEMATOLOGY ..... 62
7.6 OTHERS ...... 63
8 GLOBAL PEGYLATED DRUGS MARKET, BY DISTRIBUTION CAHNNEL ....... 64
8.1 OVERVIEW ...... 64
8.2 HOSPITAL PHARMACY ..... 66
8.3 ONLINE PHARMACY ....... 66
8.4 RETAIL PHARMACY ..... 67
9 GLOBAL PEGYLATED DRUGS MARKET, BY REGION ...... 68
9.1 OVERVIEW ...... 68
9.2 NORTH AMERICA ...... 70
9.2.1 US ...... 74
9.2.2 CANADA ...... 76
9.3 EUROPE ...... 78
9.3.1 GERMANY ....... 82
9.3.2 FRANCE ....... 84
9.3.3 UK ...... 85
9.3.4 ITALY ..... 87
9.3.5 SPAIN ....... 89
9.3.6 REST OF EUROPE ..... 91
9.4 ASIA-PACIFIC ....... 93
9.4.1 CHINA ...... 96
9.4.2 INDIA ..... 98
9.4.3 JAPAN ...... 100
9.4.4 AUSTRALIA ..... 101
9.4.5 SOUTH KOREA ...... 103
9.4.6 REST OF ASIA-PACIFIC ...... 104
9.5 REST OF THE WORLD ..... 107
9.5.1 MIDDLE EAST & AFRICA ....... 110
9.5.2 SOUTH AMERICA...... 112
9.5.2.1 BRAZIL ....... 114
9.5.2.2 MEXICO ...... 115
9.5.2.3 ARGENTINA ...... 117
9.5.2.4 REST OF SOUTH AMERICA ..... 119
10 COMPETITIVE LANDSCAPE ..... 122
10.1 INTRODUCTION ...... 122
10.2 MARKET SHARE ANALYSIS, 2024 ...... 122
10.3 COMPETITOR DASHBOARD ...... 123
10.4 PUBLIC PLAYERS STOCK SUMMARY ...... 124
10.5 CMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL ....... 125
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES ...... 126
10.6.1 PRODUCT APPROVAL ..... 126
10.6.2 PRODUCT EXPANSION ...... 127
10.6.3 APPROVAL DENIED ..... 127
10.6.4 PRODUCT DISCONTINUATION..... 127
10.6.5 AGREEMENT/ACQUISITION ..... 128
10.6.6 CLINICAL TRIAL FINDINGS ...... 128
11 COMPANY PROFILES ...... 129
11.1 AMGEN INC. ....... 129
11.1.1 COMPANY OVERVIEW ....... 129
11.1.2 FINANCIAL OVERVIEW....... 130
11.1.3 PRODUCTS OFFERED ...... 131
11.1.4 KEY DEVELOPMENTS ..... 131
11.1.5 SWOT ANALYSIS ...... 132
11.1.6 KEY STRATEGIES ..... 132
11.2 PFIZER INC. ..... 133
11.2.1 COMPANY OVERVIEW ....... 133
11.2.2 FINANCIAL OVERVIEW....... 135
11.2.3 PRODUCTS OFFERED ...... 136
11.2.4 KEY DEVELOPMENTS ..... 136
11.2.5 SWOT ANALYSIS ...... 136
11.2.6 KEY STRATEGIES ..... 137
11.3 BIOGEN ...... 138
11.3.1 COMPANY OVERVIEW ....... 138
11.3.2 FINANCIAL OVERVIEW....... 139
11.3.3 PRODUCTS OFFERED ...... 140
11.3.4 KEY DEVELOPMENTS ..... 140
11.3.5 KEY STRATEGIES ..... 140
11.4 BAYER AG ..... 141
11.4.1 COMPANY OVERVIEW ....... 141
11.4.2 FINANCIAL OVERVIEW....... 142
11.4.3 PRODUCTS OFFERED ...... 142
11.4.4 KEY DEVELOPMENTS ..... 143
11.4.5 SWOT ANALYSIS ...... 143
11.4.6 KEY STRATEGY ..... 144
11.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED..... 145
11.5.1 COMPANY OVERVIEW ...... 145
11.5.2 FINANCIAL OVERVIEW....... 146
11.5.3 PRODUCT OFFERED ..... 146
11.5.4 KEY DEVELOPMENTS ..... 147
11.5.5 KEY STRATEGIES ..... 147
11.6 NOVO NORDISK A/S ..... 148
11.6.1 COMPANY OVERVIEW ....... 148
11.6.2 FINANCIAL OVERVIEW....... 149
11.6.3 PRODUCTS OFFERED ...... 150
11.6.4 KEY DEVELOPMENTS ..... 150
11.6.5 SWOT ANALYSIS ...... 151
11.6.6 KEY STRATEGIES ..... 151
11.7 SANDOZ GROUP AG ..... 152
11.7.1 COMPANY OVERVIEW ....... 152
11.7.2 FINANCIAL OVERVIEW....... 153
11.7.3 PRODUCTS OFFERED ...... 154
11.7.4 KEY DEVELOPMENTS ..... 154
11.7.5 KEY STRATEGIES ..... 154
11.8 ASTRAZENECA ..... 155
11.8.1 COMPANY OVERVIEW ....... 155
11.8.2 FINANCIAL OVERVIEW....... 156
11.8.3 PRODUCTS OFFERED ...... 157
11.8.4 KEY DEVELOPMENTS ..... 157
11.8.5 KEY STRATEGIES ..... 157
11.9 COHERUS BIOSCIENCES, INC. ...... 158
11.9.1 COMPANY OVERVIEW ....... 158
11.9.2 FINANCIAL OVERVIEW....... 159
11.9.3 PRODUCTS OFFERED ...... 160
11.9.4 KEY DEVELOPMENTS ..... 160
11.9.5 KEY STRATEGIES ..... 160
11.10 F. HOFFMANN-LA ROCHE LTD. ...... 161
11.10.1 COMPANY OVERVIEW ....... 161
11.10.2 FINANCIAL OVERVIEW ...... 162
11.10.3 PRODUCTS OFFERED ..... 163
11.10.4 KEY DEVELOPMENTS ..... 163
11.10.5 SWOT ANALYSIS ..... 163
11.10.6 KEY STRATEGIES ..... 164
11.11 JOHNSON & JOHNSON INC. ....... 165
11.11.1 COMPANY OVERVIEW ....... 165
11.11.2 FINANCIAL OVERVIEW ...... 166
11.11.3 PRODUCTS OFFERED ..... 167
11.11.4 KEY DEVELOPMENTS ..... 167
11.11.5 SWOT ANALYSIS ..... 167
11.11.6 KEY STRATEGIES ..... 168
11.12 ALNYLAM PHARMACEUTICALS, INC. ....... 169
11.12.1 COMPANY OVERVIEW ....... 169
11.12.2 FINANCIAL OVERVIEW ...... 170
11.12.3 PRODUCTS OFFERED ..... 170
11.12.4 KEY DEVELOPMENTS ..... 171
11.12.5 KEY STRATEGIES ..... 171
11.13 LES LABORATOIRES SERVIER ...... 172
11.13.1 COMPANY OVERVIEW ....... 172
11.13.2 FINANCIAL OVERVIEW ...... 172
11.13.3 PRODUCT OFFERED ....... 173
11.13.4 KEY DEVELOPMENTS ..... 173
11.13.5 KEY STRATEGIES ..... 173
12 DATA CITATIONS ....... 174

언급된 주요 기업들

Novo Nordisk A/S, AstraZeneca, Pfizer, Inc., Amgen, Inc., Biogen, Takeda Pharmaceutical Company Limited, Bayer AG, F.Hoffmann La-Roche, Sandoz Group AG, Coherus BioSciences, Inc.

표 목록 (Tables)

LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 34
TABLE 2 RECENTLY APPROVED PEGYLATED DRUGS IN U.S., AUSTRALIA, JAPAN, AND CANADA 41
TABLE 3 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 53
TABLE 4 GLOBAL PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY REGION, 2019–2035 (USD MILLION) 54
TABLE 5 GLOBAL PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 55
TABLE 6 GLOBAL PEGYLATED DRUGS MARKET, FOR PROTEIN AND PEPTIDE, BY REGION, 2019–2035 (USD MILLION) 55
TABLE 7 GLOBAL PEGYLATED DRUGS MARKET, FOR ENZYME, BY REGION, 2019–2035 (USD MILLION) 56
TABLE 8 GLOBAL PEGYLATED DRUGS MARKET, FOR APTAMER, BY REGION, 2019–2035 (USD MILLION) 56
TABLE 9 GLOBAL PEGYLATED DRUGS MARKET, FOR SMALL MOLECULAR DRUGS, BY REGION, 2019–2035 (USD MILLION) 57
TABLE 10 GLOBAL PEGYLATED DRUGS MARKET, FOR LIPID NANOPARTICLES (LNP) AND LIPOSOMES, BY REGION, 2019–2035 (USD MILLION)
57
TABLE 11 GLOBAL PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 60
TABLE 12 GLOBAL PEGYLATED DRUGS MARKET, FOR ONCOLOGY, BY REGION, 2019–2035 (USD MILLION) 61
TABLE 13 GLOBAL PEGYLATED DRUGS MARKET, FOR NEUROLOGY, BY REGION, 2019–2035 (USD MILLION) 61
TABLE 14 GLOBAL PEGYLATED DRUGS MARKET, FOR AUTOIMMUNE DISEASES, BY REGION, 2019–2035 (USD MILLION) 62
TABLE 15 GLOBAL PEGYLATED DRUGS MARKET, FOR HAEMATOLOGY, BY REGION, 2019–2035 (USD MILLION) 62
TABLE 16 GLOBAL PEGYLATED DRUGS MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD MILLION) 63
TABLE 17 GLOBAL PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 65
TABLE 18 GLOBAL PEGYLATED DRUGS MARKET, FOR HOSPITAL PHARMACY, BY REGION, 2019–2035 (USD MILLION) 66
TABLE 19 GLOBAL PEGYLATED DRUGS MARKET, FOR ONLINE PHARMACY, BY REGION, 2019–2035 (USD MILLION) 66
TABLE 20 GLOBAL PEGYLATED DRUGS MARKET, FOR RETAIL PHARMACY, BY REGION, 2019–2035 (USD MILLION) 67
TABLE 21 GLOBAL PEGYLATED DRUGS MARKET, BY REGION, 2019–2035 (USD MILLION) 69
TABLE 22 NORTH AMERICA PEGYLATED DRUGS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 71
TABLE 23 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 72
TABLE 24 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 73
TABLE 25 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 73
TABLE 26 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 74
TABLE 27 US: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 74
TABLE 28 US: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 74
TABLE 29 US: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 75
TABLE 30 US: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 75
TABLE 31 CANADA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 76
TABLE 32 CANADA: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 76
TABLE 33 CANADA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 77
TABLE 34 CANADA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 77
TABLE 35 EUROPE PEGYLATED DRUGS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 79
TABLE 36 EUROPE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 80
TABLE 37 EUROPE: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 80
TABLE 38 EUROPE: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 81
TABLE 39 EUROPE: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 81
TABLE 40 GERMANY: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 82
TABLE 41 GERMANY: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 82
TABLE 42 GERMANY: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 83
TABLE 43 GERMANY: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 83
TABLE 44 FRANCE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 84
TABLE 45 FRANCE: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 84
TABLE 46 FRANCE: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 84
TABLE 47 FRANCE: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 85
TABLE 48 UK: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 85
TABLE 49 UK: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 86
TABLE 50 UK: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 86
TABLE 51 UK: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 86
TABLE 52 ITALY: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 87
TABLE 53 ITALY: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 87
TABLE 54 ITALY: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 88
TABLE 55 ITALY: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 88
TABLE 56 SPAIN: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 89
TABLE 57 SPAIN: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 89
TABLE 58 SPAIN: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 90
TABLE 59 SPAIN: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 90
TABLE 60 REST OF EUROPE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 91
TABLE 61 REST OF EUROPE: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 91
TABLE 62 REST OF EUROPE: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 92
TABLE 63 REST OF EUROPE: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 92
TABLE 64 ASIA-PACIFIC PEGYLATED DRUGS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 94
TABLE 65 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 95
TABLE 66 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 95
TABLE 67 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 95
TABLE 68 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 96
TABLE 69 CHINA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 96
TABLE 70 CHINA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 97
TABLE 71 CHINA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 97
TABLE 72 CHINA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 97
TABLE 73 INDIA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 98
TABLE 74 INDIA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 98
TABLE 75 INDIA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 99
TABLE 76 INDIA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 99
TABLE 77 JAPAN: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 100
TABLE 78 JAPAN: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 100
TABLE 79 JAPAN: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 100
TABLE 80 JAPAN: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 101
TABLE 81 AUSTRALIA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 101
TABLE 82 AUSTRALIA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 102
TABLE 83 AUSTRALIA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 102
TABLE 84 AUSTRALIA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 102
TABLE 85 SOUTH KOREA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 103
TABLE 86 SOUTH KOREA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 103
TABLE 87 SOUTH KOREA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 104
TABLE 88 SOUTH KOREA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 104
TABLE 89 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 104
TABLE 90 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 105
TABLE 91 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 105
TABLE 92 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 106
TABLE 93 REST OF THE WORLD PEGYLATED DRUGS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 108
TABLE 94 REST OF THE WORLD: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 108
TABLE 95 REST OF THE WORLD: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 109
TABLE 96 REST OF THE WORLD: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 109
TABLE 97 REST OF THE WORLD: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 109
TABLE 98 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 110
TABLE 99 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 110
TABLE 100 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 111
TABLE 101 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 111
TABLE 102 SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 112
TABLE 103 SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 112
TABLE 104 SOUTH AMERICA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 112
TABLE 105 SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 113
TABLE 106 SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 113
TABLE 107 BRAZIL: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 114
TABLE 108 BRAZIL: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 114
TABLE 109 BRAZIL: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 115
TABLE 110 BRAZIL: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 115
TABLE 111 MEXICO: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 115
TABLE 112 MEXICO: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 116
TABLE 113 MEXICO: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 116
TABLE 114 MEXICO: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 117
TABLE 115 ARGENTINA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 117
TABLE 116 ARGENTINA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 117
TABLE 117 ARGENTINA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 118
TABLE 118 ARGENTINA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 118
TABLE 119 REST OF SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 119
TABLE 120 REST OF SOUTH AMERICA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 119
TABLE 121 REST OF SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 120
TABLE 122 REST OF SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 120
TABLE 123 PRODUCT APPROVAL 126
TABLE 124 PRODUCT EXPANSION 127
TABLE 125 APPROVAL DENIED 127
TABLE 126 PRODUCT DISCONTINUATION 127
TABLE 127 AGREEMENT/ACQUISITION 128
TABLE 128 CLINICAL TRIAL FINDINGS 128
TABLE 129 AMGEN INC.: PRODUCTS OFFERED
TABLE 130 AMGEN INC.: KEY DEVELOPMENTS
TABLE 131 PFIZER INC.: PRODUCTS OFFERED
TABLE 132 PFIZER INC.: KEY DEVELOPMENTS
TABLE 133 BIOGEN: PRODUCTS OFFERED
TABLE 134 BIOGEN: KEY DEVELOPMENTS
TABLE 135 BAYER AG: PRODUCTS OFFERED
TABLE 136 BAYER AG: KEY DEVELOPMENTS
TABLE 137 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS OFFERED
TABLE 138 TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY DEVELOPMENTS
TABLE 139 NOVO NORDISK A/S: PRODUCTS OFFERED
TABLE 140 NOVO NORDISK A/S: KEY DEVELOPMENTS
TABLE 141 SANDOZ GROUP AG: PRODUCTS OFFERED
TABLE 142 SANDOZ GROUP AG: KEY DEVELOPMENTS
TABLE 143 ASTRAZENECA: PRODUCTS OFFERED
TABLE 144 ASTRAZENECA: KEY DEVELOPMENTS
TABLE 145 COHERUS BIOSCIENCES, INC.: PRODUCTS OFFERED
TABLE 146 COHERUS BIOSCIENCES, INC.: KEY DEVELOPMENTS
TABLE 147 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
TABLE 148 JOHNSON & JOHNSON INC.: PRODUCTS OFFERED
TABLE 149 ALNYLAM PHARMACEUTICALS, INC: PRODUCTS OFFERED
TABLE 150 ALNYLAM PHARMACEUTICALS, INC: KEY DEVELOPMENTS
TABLE 151 LES LABORATOIRES SERVIER: PRODUCTS OFFERED

그림 목록 (Figures)

LIST OF FIGURES
FIGURE 1 GLOBAL PEGYLATED DRUGS MARKET: STRUCTURE 21
FIGURE 2 GLOBAL PEGYLATED DRUGS MARKET: MARKET GROWTH FACTOR ANALYSIS (2024-2035) 39
FIGURE 3 DRIVER IMPACT ANALYSIS (2024-2035) 42
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2024-2035) 44
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL PEGYLATED DRUGS MARKET 46
FIGURE 6 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE, 2024 & 2035 (USD MILLION) 53
FIGURE 7 GLOBAL PEGYLATED DRUGS MARKET SHARE (%), BY MOLECULE, 2024 54
FIGURE 8 GLOBAL PEGYLATED DRUGS MARKET, BY APPLICATION, 2024 & 2035 (USD MILLION) 59
FIGURE 9 GLOBAL PEGYLATED DRUGS MARKET SHARE (%), BY APPLICATION, 2024 60
FIGURE 10 GLOBAL PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 & 2035 (USD MILLION) 64
FIGURE 11 GLOBAL PEGYLATED DRUGS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2024 65
FIGURE 12 GLOBAL PEGYLATED DRUGS MARKET SHARE, BY REGION, 2024 & 2035 (USD MILLION) 68
FIGURE 13 GLOBAL PEGYLATED DRUGS MARKET SHARE, BY REGION, 2024 (%) 69
FIGURE 14 NORTH AMERICA PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION) 71
FIGURE 15 NORTH AMERICA PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 (%) 72
FIGURE 16 EUROPE PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION) 78
FIGURE 17 EUROPE PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 (%) 79
FIGURE 18 ASIA-PACIFIC PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION) 93
FIGURE 19 ASIA-PACIFIC PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 (%) 94
FIGURE 20 REST OF THE WORLD PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION) 107
FIGURE 21 REST OF THE WORLD PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 (%) 108
FIGURE 22 GLOBAL PEGYLATED DRUGS MARKET PLAYERS: COMPETITIVE ANALYSIS, 2024 122
FIGURE 23 COMPETITOR DASHBOARD: GLOBAL PEGYLATED DRUGS MARKET 123
FIGURE 24 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT 130
FIGURE 25 AMGEN INC.: SWOT ANALYSIS 132
FIGURE 26 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT 135
FIGURE 27 PFIZER INC.: SWOT ANALYSIS 136
FIGURE 28 BIOGEN: FINANCIAL OVERVIEW SNAPSHOT 139
FIGURE 29 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT 142
FIGURE 30 BAYER AG: SWOT ANALYSIS 143
FIGURE 31 TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIAL OVERVIEW SNAPSHOT 146
FIGURE 32 NOVO NORDISK A/S: FINANCIAL OVERVIEW SNAPSHOT 149
FIGURE 33 NOVO NORDISK A/S: SWOT ANALYSIS 151
FIGURE 34 SANDOZ GROUP AG: FINANCIAL OVERVIEW SNAPSHOT 153
FIGURE 35 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT 156
FIGURE 36 COHERUS BIOSCIENCES, INC.: FINANCIAL OVERVIEW SNAPSHOT 159
FIGURE 37 F. HOFFMANN-LA ROCHE LTD.: FINANCIAL OVERVIEW SNAPSHOT 162
FIGURE 38 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 163
FIGURE 39 JOHNSON & JOHNSON INC.: FINANCIAL OVERVIEW SNAPSHOT 166
FIGURE 40 JOHNSON & JOHNSON INC.: SWOT ANALYSIS 167
FIGURE 41 ALNYLAM PHARMACEUTICALS, INC: FINANCIAL OVERVIEW SNAPSHOT 170

페길화 의약품 시장 규모 및 2035년까지의 전망

Pegylated Drugs Market Size and Forecast till 2035